Determination of zafirlukast, a selective leukotriene antagonist, human plasma by normal-phase high-performance liquid chromatography with fluorescence detection
被引:21
作者:
Bui, KH
论文数: 0引用数: 0
h-index: 0
机构:Drug Disposition and Metab. Dept., ZENECA Pharmaceuticals, Wilmington, DE 19897
Bui, KH
Kennedy, CM
论文数: 0引用数: 0
h-index: 0
机构:Drug Disposition and Metab. Dept., ZENECA Pharmaceuticals, Wilmington, DE 19897
Kennedy, CM
Azumaya, CT
论文数: 0引用数: 0
h-index: 0
机构:Drug Disposition and Metab. Dept., ZENECA Pharmaceuticals, Wilmington, DE 19897
Azumaya, CT
Birmingham, BK
论文数: 0引用数: 0
h-index: 0
机构:Drug Disposition and Metab. Dept., ZENECA Pharmaceuticals, Wilmington, DE 19897
Birmingham, BK
机构:
[1] Drug Disposition and Metab. Dept., ZENECA Pharmaceuticals, Wilmington, DE 19897
[2] E.I. du Pont de Nemours and Company, DuPont Agricultural Products, Experimental Station, Wilmington
来源:
JOURNAL OF CHROMATOGRAPHY B
|
1997年
/
696卷
/
01期
关键词:
zafirlukast;
D O I:
10.1016/S0378-4347(97)00092-3
中图分类号:
Q5 [生物化学];
学科分类号:
071010 ;
081704 ;
摘要:
A high-performance liquid chromatographic (HPLC) method was developed for the determination of zafirlukast, a selective peptide leukotriene receptor antagonist, in human plasma. Zafirlukast and the internal standard, ICI 198 707, were extracted from deproteinated plasma samples using large reservoir C-18 solid-phase extraction columns and analyzed by normal-phase liquid chromatography with fluorescence detection. The method had a lower limit of quantitation of 0.75 ng/ml and a linear calibration curve in the range of 0.75 to 200 ng/ml. The absolute recovery of zafirlukast was >90%, and the within-day and between-day relative standard deviations were <9%. The utility of the method in the characterization of the plasma concentration-time profiles of zafirlukast in clinical studies was demonstrated. (C) 1997 Elsevier Science B.V.